IDH1 R132H mutation is a rare event in myeloproliferative neoplasms as determined by a mutation specific antibody.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. The potential applications of peptide-loading complex in cancer treatment.Frontiers in immunology · 2025
   Review
2. [Predictive molecular pathological stratification of hematological neoplasms].Der Pathologe · 2016
   Review
3. Diagnostic testing for IDH1 and IDH2 variants in acute myeloid leukemia an algorithmic approach using high-resolution melting curve analysis.The Journal of molecular diagnostics : JMD · 2011
   Article
4. IDH1 and IDH2 mutations in myeloid neoplasms--novel paradigms and clinical implications.Haematologica · 2010
   Article
5. Newly Identified Characteristics and Suggestions for Diagnosis and Treatment of Diffuse Leptomeningeal Glioneuronal/Neuroepithelial Tumors: A Case Report and Review of the Literature.Child neurology open
   Article

Corrections and comments

• Commented on by
  IDH1 and IDH2 mutations in myeloid neoplasms--novel paradigms and clinical implications.2010

Authors and funding

7 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as